Gene · 3568
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pro-inflammatory and counter-regulatory modulators of interleukin-5-driven eosinophil programs: a framework for precision medicine in eosinophilic diseases. | Front Immunol | 2026 | 42058205 | PubTator, text mining | PubMed |
| Expert review and recommendations on the diagnosis and therapeutic management of eosinophilic granulomatosis with polyangiitis. | Front Immunol | 2026 | 42051495 | PubTator, text mining | PubMed |
| Rapid & sustained benefit of benralizumab in severe eosinophilic asthma: the BE-REAL study. | Respir Med | 2026 | 42044815 | PubTator, text mining | PubMed |
| Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy. | Front Immunol | 2026 | 42039188 | PubTator, text mining | PubMed |
| Dupilumab-induced eosinophilia in severe asthma: 2-year follow-up real-life evidence from biologic-naïve and previously treated patients. | Respir Med | 2026 | 42036049 | PubTator, text mining | PubMed |
| Clinical Remission in Severe T2-High Asthma in Real Life After Anti-IgE, Anti-IL-5 and Anti-IL5R: A Potential Role for CRP as a Biomarker. | Clin Transl Allergy | 2026 | 41987495 | PubTator, text mining | PubMed |
| Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma. | Cancers (Basel) | 2026 | 41976339 | PubTator, text mining | PubMed |
| Expanded peripheral CD62Llow inflammatory eosinophils in pediatric thunderstorm-related asthma exacerbations: A single-center analysis. | Pediatr Allergy Immunol | 2026 | 41968404 | PubTator, text mining | PubMed |
| Individualized precision therapy for severe asthma: clinical applications of biological agents and frontiers of cell therapy. | Front Immunol | 2026 | 41948320 | PubTator, text mining | PubMed |
| Systemic vasculitis: one year in review 2026. | Clin Exp Rheumatol | 2026 | 41930663 | PubTator, text mining | PubMed |
| Chronic spontaneous urticaria treatments and purinergic signaling: a therapeutic possibility. | J Mol Med (Berl) | 2026 | 41917502 | PubTator, text mining | PubMed |
| Understanding Biologics in CRSwNP: Related Events and Insights. | Curr Allergy Asthma Rep | 2026 | 41910874 | PubTator, text mining | PubMed |
| Eosinophilic granulomatosis with polyangiitis across the eosinophilic spectrum: from molecular mechanisms to practical differential diagnosis and targeted therapy. | Reumatologia | 2026 | 41909063 | PubTator, text mining | PubMed |
| Preliminary Effects of Benralizumab in an AML Cell Model with Promyelocytic Features Expressing IL-5R: An Exploratory Proof-of-Concept Study. | Biomedicines | 2026 | 41898298 | PubTator, text mining | PubMed |
| Real-World Effectiveness of Tezepelumab in Severe Asthma: A Comparative Analysis of High and Low T2 Phenotypes. | J Pers Med | 2026 | 41893035 | PubTator, text mining | PubMed |
| Understanding Eosinophil Heterogeneity: The Known and Unknown. | Cells | 2026 | 41892353 | PubTator, text mining | PubMed |
| Interleukin-35 as a key immunoregulatory mediator in steroid-hyporesponsive severe asthma. | Front Immunol | 2026 | 41869316 | PubTator, text mining | PubMed |
| Predicting clinical remission in biologic-treated severe asthma: development of a practical scoring system from a Japanese multicentre study. | BMJ Open Respir Res | 2026 | 41850735 | PubTator, text mining | PubMed |
| Biologics for eosinophilic COPD: current applications and future prospects. | Front Immunol | 2026 | 41836441 | PubTator, text mining | PubMed |
| Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis. | ERJ Open Res | 2026 | 41809856 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3568/papers?page=3